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liver damage has increased [5,6]. In April 2003, the
Spanish Agency of Medicine and Health Products with-
drew the over the counter medicine Exolise from the
market. This contained an ethanolic extract of green
tea, and was the cause of four cases of hepatotoxicity
in Spain [7] and nine in France [8]. In none of the Her-
balife products containing green tea is the type of ex-
tract or the amount of active substances speciﬁed. On
the other hand, several authors [9–11] have reported
cases of acute hepatitis associated with the consumption
of Aloe vera tablets or capsules. Aloe vera is the main
component of the drink Herbal Aloe sold by Herbalife.
We do not believe that the hepatotoxicity of the Her-
balife products is conﬁned to three countries alone.
The lower use in some areas, the underreporting of ad-
verse reactions, and the lower ability to detect or report
information in the international scientiﬁc media could
be the reasons for explaining this lack of information
from other countries. For some time, Latin American
and Spanish health professionals have been discussing
the safety of Herbalife products and similar com-
pounds on internet forums.
Schoepfer et al. [2] and Stickel [3] consider that the
hepatotoxicity associated with Herbalife products does
not seem to be a threat to public health and have sug-
gested an incidence lower than that of the non-steroidal
anti-inﬂammatory drugs. In our opinion, the evaluation
of this safety problem is impossible because we have no
precise consumption data nor isolated active substances
of established eﬃcacy. Perhaps the hepatotoxicity we are
speaking about is of low incidence and aﬀects patients
with genetic susceptibility or other risk factors. How-
ever, the growing consumption of products promoted
as ‘‘natural”, without deﬁned composition, quality con-
trol and demonstrated activity and safety is a real health
problem that should be kept under control. Today we
are speaking only about the products of the Herbalife
brand, but tomorrow we may be speaking about other
products or other brands.
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More reports of potential hepatotoxicity of Herbalife products: Reply
To the Editor:
The Letter to the Editor by Manso and colleagues
from Spain [1] reiterates the deep concern recently raised
[2–4] regarding the potential hepatotoxicity of one or
more HerbalifeTM products. This report adds 4 more
patients to the already described 22 patients from two
countries, who developed a variable degree of liver
injury in association with the intake of HerbalifeTM
products.
Two of the Spanish patients developed quite severe
hepatitis with jaundice and 3/4 recovered after stopping
intake of the products. Although the information pro-
vided is not complete, causality may be established in
at least two cases as probable and in the remaining
two cases as possible, based on the same criteria as re-
ported in Ref. [2–4].The development of hepatitis in
two sisters, one of whom has or progressed to chronic
hepatitis, is an important observation which may shed
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further light on the potential mechanism of hepatotoxic-
ity in these sisters. Although it cannot be established for
certain if autoimmunity or a pharmaco-genetic prepon-
derance is the driving force behind these events, the reac-
tive hepatitis in the two sisters suggests a common
mechanism. Dr. Manso et al. raise the possibility that
green tea or aloe vera ingredients, previously reported
to induce hepatotoxicity may also be the cause in the
Spanish group of patients. However, these ingredients
were not taken uniformly by all the reported patients
from Israel and Switzerland, and therefore a detailed list
of all the ingredients including the chemical composition
is required as stated in the two original reports. In Spain
as well as in Israel and Switzerland, it was not possible
to establish the true incidence of hepatotoxicity among
HerbalifeTM users since the number of consumers and
their demographic characteristics are only partially
known. A rough calculation suggested an incidence of
25–30 cases per 100,000 HerbalifeTM products among Is-
raeli consumers. We agree with the colleagues from
Spain that the true incidence may be higher since liver
injury may remain occult and asymptomatic as is well
known by practising hepatologists. Thus, it is important
to draw the attention of the Journals readers to reports
of similar cases.
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Herbalife nutritional products and liver injury revisited
To the Editor:
Recently, two reports of 12 and 10 cases of idio-
pathic liver disease from Israel [1] and Switzerland
[2], respectively, appeared in the same issue of this
journal alleging in the articles and in an accompanying
editorial that these cases were caused by the consump-
tion of Herbalife products. In fact, the two papers [1,2]
concluded unequivocally that causation was certain in
some cases. Despite the authors’ strong assertion that
a cause and eﬀect relationship between Herbalife prod-
uct use and liver injury exists, an objective review of
the facts raises serious doubt whether such a conclu-
sion can be drawn. In Israel [1], the observed liver
abnormalities resolved in eleven of the twelve cases re-
ported. The remaining patient succumbed to complica-
tions of liver transplantation and despite the fact that
this patient also had evidence of hepatitis B infection,
sole attribution of the liver injury to Herbalife products
was made. Another patient had stage I primary biliary
cirrhosis and other patients consumed a variety of sub-
stances or had other co-morbid diseases that could
have caused or contributed to the liver disease ob-
served. In Switzerland [2], a total of 10 evaluable case
reports with similar characteristics were documented
over seven years.
Taken at face value, these few cases represent an ex-
tremely low incidence of suspected liver injury among
the millions of Herbalife consumers worldwide (5.5 mil-
lion consumers in 2004 alone). In 2004 more than
40,000,000 servings from 29 diﬀerent products were dis-
tributed to approximately 37,000 Israeli consumers. A
similar number of servings from 26 diﬀerent products
were distributed to approximately 80,000 Swiss consum-
ers. In the 5 combined cases where causation was
assessed as ‘‘certain” due to a reported combination of
positive dechallenge and rechallenge, the case details
remain unclear. As an example, 4 of these patients
described between 3 and 17 diﬀerent and speciﬁc Herba-
life products previously consumed prior to dechallenge,
and in the remaining patient no speciﬁc Herbalife prod-
uct in either the reported dechallenge or rechallenge
could be identiﬁed. Equally concerning is the fact that
there is no mention of which of the initially reported
products were subsequently consumed by any of the pa-
tients that allegedly led to the recurrence of symptoms.
Even if all 4 patients consumed the exact same 3–17
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